NASDAQ$SYRS
Syros Pharmaceuticals Inc · Q3 2024 earnings
Q3 2024 earnings · · Investor relations
Briefing
SYRS Q3 2024 — $3.8M revenue, 39.00 EPS
SELECT-MDS-1 or any future clinical trials, whether conducted by us or by any collaborators, including the timing of these trials and of the anticipated results;. Syros Pharmaceuticals Inc reported Q3 2024 results. Diluted EPS came in at $39.00. Headline numbers extracted from the Form 10-Q press release; narrative is light because this row was processed without an LLM call.
- Revenue: $3.8M.
- Diluted EPS: $39.00.
- Operating income: $26K.
Headline financials
Revenue & EPS history
Syros · Revenue · Quarterly
$3.76M
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2024
+2.5%
Avg return
Earnings day
+2.5%
Avg return
5 days after
-5.0%
Avg return
30 days after
61%
23 / 38 earnings
Positive
+43.9%
Q2 2016
Best reaction
-14.4%
Q4 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q3 2025 | +0.0% | +50.0% | +25.0% | |
| Q2 2025 | +10.0% | -45.0% | -95.0% | |
| Q1 2025 | -10.4% | -7.6% | -40.2% | |
| Q4 2024 | +14.3% | +11.1% | -14.3% | |
| Q3 2024 | -9.6% | +0.8% | -89.2% | |
| Q2 2024 | -9.4% | -16.9% | -73.8% | |
| Q1 2024 | +8.9% | +7.7% | +14.6% | |
| Q4 2023 | -14.4% | -19.4% | -19.4% | |
| Q3 2023 | +13.0% | +10.8% | +61.0% | |
| Q2 2023 | +1.4% | +3.8% | +5.2% | |
| Q1 2023 | +6.8% | +20.9% | +14.1% | |
| Q4 2022 | +7.4% | +9.8% | -27.0% | |
| Q3 2022 | +0.8% | +2.5% | -7.0% | |
| Q2 2022 | -1.5% | -2.1% | -29.2% | |
| Q1 2022 | -13.6% | -19.3% | +19.0% | |
| Q4 2021 | +2.8% | +8.4% | -15.3% | |
| Q3 2021 | -1.4% | -4.5% | -19.7% | |
| Q2 2021 | +4.0% | +2.0% | +17.5% | |
| Q1 2021 | -5.1% | -5.3% | +6.9% | |
| Q4 2020 | -4.6% | -1.1% | -11.2% | |
| Q3 2020 | +2.2% | +0.2% | -6.1% | |
| Q2 2020 | +8.2% | +6.5% | -12.1% | |
| Q1 2020 | +6.6% | +1.3% | -3.4% | |
| Q4 2019 | +5.8% | -15.4% | -2.4% | |
| Q3 2019 | +5.0% | +0.0% | -7.4% | |
| Q2 2019 | +8.3% | +5.6% | +46.7% | |
| Q1 2019 | -5.4% | -3.2% | -18.4% | |
| Q4 2018 | -8.9% | +3.3% | +5.8% | |
| Q3 2018 | +17.9% | +22.5% | +3.5% | |
| Q2 2018 | +14.8% | +21.7% | +17.8% | |
| Q1 2018 | +2.5% | +3.0% | +2.6% | |
| Q4 2017 | +5.0% | +6.2% | +11.4% | |
| Q3 2017 | -5.1% | -4.9% | +1.0% | |
| Q2 2017 | -7.7% | +0.4% | -24.7% | |
| Q1 2017 | +12.2% | +15.7% | +16.4% | |
| Q4 2016 | -8.2% | -4.1% | -4.8% | |
| Q3 2016 | +0.4% | -2.9% | +11.8% | |
| Q2 2016 | +43.9% | +33.7% | +50.4% | |
| Q1 2016 | — | — | — | |
| Q4 2015 | — | — | — | |
| Q3 2015 | — | — | — | |
| Q2 2015 | — | — | — | |
| Q1 2015 | — | — | — | |
| Q4 2014 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro